Great news - UP UP UP Med BioGene licensee Precision finishes studies
2013-01-23 08:42 ET - News Release
This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.
Here is a sample of this item:
Ms. Erinn Broshko reports
PRECISION THERAPEUTICS AND MED BIOGENE ANNOUNCE SUCCESSFUL COMPLETION OF LUNGEXPRESS DX(TM) CLINICAL STUDIES; PRECISION THERAPEUTICS PREPARES FOR COMMERCIAL LAUNCH
Med BioGene Inc. licensee Precision Therapeutics Inc. has successfully completed their previously announced clinical studies to validate the use of LungExpress Dx(TM) with tissue preserved by RNAlaterAtrademark, a molecular fixative.
RNAlater eliminates the need to flash-freeze specimens and to keep specimens frozen throughout storage and transport, a process that can be cumbersome and costly. It also eliminates the need for preserving tissue in formalin, which is known to cross-link and degrade the nucleic acids rendering them less suitable for specific downstream molecular applications.
The clinical studies were conducted using patient specimens prospectively accrued by Precision from a consortium of medical centers in the United States.
Precision expects to commence commercialization of LungExpress Dx in its CLIA-certified laboratory by mid-2013. In advance of commercialization, Precision has established an advisory board comprised of world leaders in lung cancer research and treatment from the United States, Canada, France and Italy.